Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.

Biotechnology

Neurogene

Rachel McMinn

Jerry Lugo

Danielle Boyle

Tina Parikh

Kimberly Trant, RN, MBA

Ellery Mangas

Efsevia (Effie) Albanis

Craig Hebel

Bridget M.

Anandita Seth

Albena Patroneva

Andrew Mulberg

Christine Mikail

Ricardo Jimenez

Stuart Cobb

Arvind Sreedharan

Scientific Team

Leadership Team

Clinical Operations Team

Finance and Accounting

Operations Team

Research and Development

Human Resources

Quality Assurance Team

Teams at Neurogene